Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and XOMA Royalty (NASDAQ:XOMA – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.
Insider and Institutional Ownership
95.9% of XOMA Royalty shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 7.2% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Ascendis Pharma A/S and XOMA Royalty, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ascendis Pharma A/S | 1 | 0 | 14 | 2 | 3.00 |
| XOMA Royalty | 1 | 1 | 3 | 0 | 2.40 |
Volatility & Risk
Ascendis Pharma A/S has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Profitability
This table compares Ascendis Pharma A/S and XOMA Royalty’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ascendis Pharma A/S | -35.51% | N/A | -20.56% |
| XOMA Royalty | 32.28% | 2.91% | 1.03% |
Earnings & Valuation
This table compares Ascendis Pharma A/S and XOMA Royalty”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ascendis Pharma A/S | $393.54 million | 37.07 | -$409.12 million | ($4.44) | -53.02 |
| XOMA Royalty | $28.49 million | 11.60 | -$13.82 million | $0.74 | 36.08 |
XOMA Royalty has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.
Summary
XOMA Royalty beats Ascendis Pharma A/S on 9 of the 15 factors compared between the two stocks.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
About XOMA Royalty
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
